Through PEPFAR, as of September 30, 2012, the U.S. directly supported more than 5.1 million people on antiretroviral treatment (ART). This number is up from 1.7 million in 2008 – a three-fold increase in only four years.
In FY 2012, PEPFAR programs supported antiretroviral drugs (ARV) to prevent mother-to-child transmission for more than 750,000 pregnant women living with HIV. Thanks to this effort, an estimated 230,000 infant HIV infections were averted in 2012 alone. PEPFAR also supported HIV testing and counseling for more than 46.5 million people in 2012.